Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Mater Chem B ; 9(48): 9946-9950, 2021 12 15.
Artigo em Inglês | MEDLINE | ID: mdl-34852032

RESUMO

Fluorescence imaging agents have recently received huge attention due to their important role in disease diagnostics. However, the intrinsic problems of these probes, such as complex synthetic routes and high molecular weight, remain challenging. Here, we developed novel phenaleno isoquinolinium-based fluorescent agents, Medical Fluorophores 37-41 (MF37-41), applicable to the quantitative and sensitive detection of sentinel lymph nodes (SLNs). These imaging agents showed no adverse effects on the proliferation of immune and normal cells and did not induce in vivo toxicity. In vivo fluorescence lifetime imaging demonstrated the accumulation of phenaleno isoquinolinium salts in the SLNs of nude mice within 15 min postinjection, consistent with our biodistribution findings. These results suggest that phenaleno isoquinolinium salts are feasible fluorescence imaging agents that can be used as potential lymphatic tracers.


Assuntos
Materiais Biocompatíveis/química , Descoberta de Drogas , Corantes Fluorescentes/química , Isoquinolinas/química , Imagem Óptica , Fenalenos/química , Linfonodo Sentinela/diagnóstico por imagem , Animais , Materiais Biocompatíveis/administração & dosagem , Materiais Biocompatíveis/síntese química , Linhagem Celular , Cricetulus , Corantes Fluorescentes/administração & dosagem , Corantes Fluorescentes/síntese química , Injeções Intravenosas , Isoquinolinas/administração & dosagem , Teste de Materiais , Camundongos , Estrutura Molecular , Fenalenos/administração & dosagem
2.
Tumour Biol ; 36(7): 5597-606, 2015 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-25722114

RESUMO

Photodynamic therapy (PDT) has been recognized as an innovated therapeutic modality for the treatment of various cancers. In this study, we evaluated the anticancer effect of a new photosensitizer 3B in breast cancer, which was considered one of the most common cancers in women worldwide. Here, we determined the effect of 3B not only on the cell growth, apoptosis, and Bcl-2 signal pathway in vitro but also on the anti-cancer effect in nude mice in vivo. Our results showed that 3B was primarily accumulated in mitochondria, increased the level of ROS, induced apoptotic cells death via Bcl-2 family, and its activity could be blocked by the caspase inhibitor (Z-VAD-FMK). In vivo study, 3B made a significant opening inhibition of tumor growth and showed drug toxicity hardly. TUNEL assay indicated that PDT group showed more positive cells (green) than other groups. These data supported that 3B might develop as potential therapeutic drug for the treatment of breast cancer.


Assuntos
Apoptose/efeitos dos fármacos , Neoplasias da Mama/genética , Imidas/administração & dosagem , Fenalenos/administração & dosagem , Fotoquimioterapia , Fármacos Fotossensibilizantes/administração & dosagem , Animais , Neoplasias da Mama/tratamento farmacológico , Neoplasias da Mama/patologia , Proliferação de Células/efeitos dos fármacos , Feminino , Humanos , Células MCF-7 , Camundongos , Mitocôndrias/efeitos dos fármacos , Mitocôndrias/patologia , Proteínas Proto-Oncogênicas c-bcl-2/biossíntese , Transdução de Sinais/efeitos dos fármacos , Ensaios Antitumorais Modelo de Xenoenxerto
3.
J Pharmacol Exp Ther ; 346(1): 11-22, 2013 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-23652222

RESUMO

Nociceptin/orphanin FQ peptide receptor (NOP) agonists produce antinociceptive effects in animal models after spinal administration and potentiate µ-opioid receptor (MOP)-mediated antinociception. This study determined the antinociceptive effects of spinally administered bifunctional NOP/MOP ligands and the antinociceptive functions of spinal NOP and MOP receptors in mice. Antinociceptive effects of bifunctional NOP/MOP ligands BU08028 [(2S)-2-[(5R,6R,7R,14S)-N-cyclopropylmethyl-4,5-epoxy-6,14-ethano-3-hydroxy-6-methoxymorphinan-7-yl]-3,3-dimethylpentan-2-ol] and SR16435 [1-(1-(2,3,3α,4,5,6-hexahydro-1H-phenalen-1-yl)piperidin-4-yl)-indolin-2-one] were pharmacologically compared with the putative bifunctional ligand buprenorphine, selective NOP agonist SCH221510 [3-endo-8-[bis(2-methylphenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]octan-3-ol] and selective MOP agonist morphine in neuropathic and inflammatory pain models. Additionally, the degree of tolerance development to the antiallodynic effects of SR16435 and buprenorphine were determined after repeated intrathecal administration. Our data indicated that BU08028 and SR16435 were more potent than morphine and SCH221510 in attenuating nerve injury-induced tactile allodynia and inflammation-induced thermal hyperalgesia. Coadministration of receptor-selective antagonists further revealed that both NOP and MOP in the spinal cord mediated the antiallodynic effects of BU08028 and SR16435, but intrathecal buprenorphine-induced antiallodynic effects were primarily mediated by MOP. Repeated intrathecal administration of SR16435 resulted in reduced and slower development of tolerance to its antiallodynic effects compared with buprenorphine. In conclusion, both NOP and MOP receptors in the spinal cord independently drive antinociception in mice. Spinally administered bifunctional NOP/MOP ligands not only can effectively attenuate neuropathic and inflammatory pain, but also have higher antinociceptive potency with reduced tolerance development to analgesia. Such ligands therefore display a promising profile as spinal analgesics.


Assuntos
Analgésicos Opioides/uso terapêutico , Modelos Animais de Doenças , Hiperalgesia/tratamento farmacológico , Neuralgia/tratamento farmacológico , Neurônios/efeitos dos fármacos , Receptores Opioides mu/metabolismo , Receptores Opioides/metabolismo , Analgésicos Opioides/administração & dosagem , Analgésicos Opioides/efeitos adversos , Raquianestesia/efeitos adversos , Raquianestesia/métodos , Animais , Compostos Azabicíclicos/administração & dosagem , Compostos Azabicíclicos/efeitos adversos , Compostos Azabicíclicos/uso terapêutico , Buprenorfina/administração & dosagem , Buprenorfina/efeitos adversos , Buprenorfina/análogos & derivados , Buprenorfina/uso terapêutico , Relação Dose-Resposta a Droga , Tolerância a Medicamentos , Hiperalgesia/imunologia , Hiperalgesia/metabolismo , Indóis/administração & dosagem , Indóis/efeitos adversos , Indóis/uso terapêutico , Injeções Espinhais , Ligantes , Masculino , Camundongos , Camundongos Endogâmicos ICR , Terapia de Alvo Molecular/efeitos adversos , Antagonistas de Entorpecentes/administração & dosagem , Antagonistas de Entorpecentes/efeitos adversos , Antagonistas de Entorpecentes/uso terapêutico , Proteínas do Tecido Nervoso/agonistas , Proteínas do Tecido Nervoso/antagonistas & inibidores , Proteínas do Tecido Nervoso/metabolismo , Neuralgia/metabolismo , Neurônios/imunologia , Neurônios/metabolismo , Fenalenos/administração & dosagem , Fenalenos/efeitos adversos , Fenalenos/uso terapêutico , Receptores Opioides/agonistas , Receptores Opioides mu/agonistas , Receptores Opioides mu/antagonistas & inibidores , Medula Espinal/efeitos dos fármacos , Medula Espinal/imunologia , Medula Espinal/metabolismo , Receptor de Nociceptina
4.
J Med Assoc Thai ; 92 Suppl 3: S29-37, 2009 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-19702066

RESUMO

INTRODUCTION: Barakol, an active constituent extracted from Cassia siamea, has been shown to have anxiolytic effects similar to diazepam when treated intraperitoneally. OBJECTIVE: Acute and chronic oral administrations of barakol on anxiolytic, locomotor and exploratory behaviors were examined in rats using an elevated plus maze followed by a holeboard apparatus in comparison with the anxiolytic diazepam. MATERIAL AND METHOD: Male Wistar rats were divided into the acute and chronic treatment groups. The acutely-treated rats were given orally with vehicle control (distilled water, p.o.), diazepam (5 mg/kg, p.o.) and barakol (10, 30 and 100 mg/kg, p.o.) while the chronically-treated rats received the same treatment for 30 consecutive days. The anxiolytic behavior was tested on the elevated plus maze for 5 min and immediately followed by the holeboard to test for the directed exploratory behavior for 10 min. RESULTS: Acute and chronic oral administration of barakol (10, 30 and 100 mg/kg, p.o.) produced no significant changes in anxiolytic parameters tested on the elevated plus maze compared to diazepam which significantly increased the percentage of the open/total time and the time spent on the open arms. On the other hand, all parameters tested using the holeboard were not affected by barakol or diazepam when given acutely. When given chronically, all doses of barakol significantly decreased the number of head-dips and the total time spent head-dipping with no changes in the number of grooms or rears per minute. CONCLUSION: Acute and chronic oral administration of barakol had no anxiolytic and locomotor effects. However, it exerted a sedative effect as shown by a reduction in the directed exploratory behaviors.


Assuntos
Ansiolíticos/farmacologia , Ansiedade/tratamento farmacológico , Benzopiranos/farmacologia , Fenalenos/farmacologia , Fitoterapia , Extratos Vegetais/farmacologia , Senna , Doença Aguda , Administração Oral , Animais , Ansiolíticos/administração & dosagem , Comportamento Animal/efeitos dos fármacos , Benzopiranos/administração & dosagem , Doença Crônica , Diazepam/administração & dosagem , Diazepam/farmacologia , Humanos , Fenalenos/administração & dosagem , Extratos Vegetais/administração & dosagem , Ratos , Ratos Wistar
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA